key: cord-1006131-ar7uw1ei
authors: Park, Jiwoon; Foox, Jonathan; Hether, Tyler; Danko, David C.; Warren, Sarah; Kim, Youngmi; Reeves, Jason; Butler, Daniel J.; Mozsary, Christopher; Rosiene, Joel; Shaiber, Alon; Afshin, Evan E.; MacKay, Matthew; Rendeiro, André F.; Bram, Yaron; Chandar, Vasuretha; Geiger, Heather; Craney, Arryn; Velu, Priya; Melnick, Ari M.; Hajirasouliha, Iman; Beheshti, Afshin; Taylor, Deanne; Saravia-Butler, Amanda; Singh, Urminder; Wurtele, Eve Syrkin; Schisler, Jonathan; Fennessey, Samantha; Corvelo, André; Zody, Michael C.; Germer, Soren; Salvatore, Steven; Levy, Shawn; Wu, Shixiu; Tatonetti, Nicholas P.; Shapira, Sagi; Salvatore, Mirella; Westblade, Lars F.; Cushing, Melissa; Rennert, Hanna; Kriegel, Alison J.; Elemento, Olivier; Imielinski, Marcin; Rice, Charles M.; Borczuk, Alain C.; Meydan, Cem; Schwartz, Robert E.; Mason, Christopher E.
title: System-wide transcriptome damage and tissue identity loss in COVID-19 patients
date: 2022-01-24
journal: Cell Rep Med
DOI: 10.1016/j.xcrm.2022.100522
sha: df9fbcafaf7f5ba24814687850fd778bcdf04560
doc_id: 1006131
cord_uid: ar7uw1ei

The molecular mechanisms underlying the clinical manifestations of COVID-19 and what distinguishes them from common seasonal influenza virus and other lung injury states such as Acute Respiratory Distress Syndrome, remains poorly understood. To address these challenges, we combine transcriptional profiling of 646 clinical nasopharyngeal swabs and 39 patient autopsy tissues to define body-wide transcriptome changes in response to COVID-19. We then match this data with spatial protein and expression profiling across 357 tissue sections from 16 representative patient lung samples and identify tissue compartment-specific damage wrought by SARS-CoV-2 infection, evident as a function of varying viral loads during the clinical course of infection and tissue type specific expression states. Overall, our findings reveal a systemic disruption of canonical cellular and transcriptional pathways across all tissues, which can inform subsequent studies to combat the mortality of COVID-19 and to better understand the molecular dynamics of lethal SARS-CoV-2 and other respiratory infections.

, an infection caused by the betacoronavirus Severe Acute 76 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), currently attributed to over 320 million cases and 77 over 5.5 million deaths globally (https://coronavirus.jhu.edu). 1 Since the presenting symptoms of 78 COVID-19 resemble those of common viral respiratory infections, a molecular diagnosis is required to 79 distinguish a SARS-CoV-2 infection from influenza and other respiratory illnesses 2, 3 , and ongoing 80 questions remain about the host responses to SARS-CoV-2 relative to other respiratory pathogens. As 81 severe illness and death continue to impact a segment of urgent 82 questions persist about the molecular drivers of morbidity and mortality associated with SARS-CoV-2 83 infection. This knowledge could lead to improvements in both the acute treatment and long-term 84 management of pathological changes in multiple organs. 85 Prior work has shown that COVID-19 leads to high systemic interferon responses (both alpha 86 and gamma), and that co-infection with other pathogens is relatively rare (3-15%). 4-6 Yet there is limited 87 data for discriminating the molecular response between different kinds of respiratory infections or 88 pulmonary conditions (e.g., IAV vs. SARS-CoV-2 infections) and almost no data on the variegated 89 impact of different pathogens across different human tissues, other than clinical observations from ICU 90 patients. 7 Delineation of pathogen-and tissue-specific differences is critical for understanding the 91 molecular determinants of mortality associated with COVID-19 and developing novel diagnostics and 92 therapeutic interventions. 93 To address this knowledge gap, we used shotgun metatranscriptomics (total RNA-seq) to 94 comprehensively profile human tissues in 39 patients who died from COVID-19 (185 total autopsy 95 samples), including heart, liver, lung, kidney, and lymph nodes, analyzed gene expression, and assessed 96 system-wide impact of SARS-CoV-2 infection. We also used a spatial protein and transcript mapping 97 platform (GeoMx) to visualize the cartography of the infection in these tissues and to discover 98 disruption of regional and cell type-specific expression. The spatial transcriptomics data examined 357 99 total regions of interest (ROIs), which were selected from 13 patients who had SARS-CoV-2, influenza, 100 or bacterial infections and from 3 normal patients as controls, revealing the cellular and regulatory 101 signatures that define these distinct pathological states. Finally, to provide context to earlier stages and 102 sites of infection, we compared these in-depth spatial and tissue-specific transcriptome maps with an 103 independent cohort of nasopharyngeal (NP) swabs from 216 COVID-19 positive patients and 430 4 examined the COVID-19 specific host responses and transcriptome changes across various organs 115 (heart, kidney, liver, lung, and lymph nodes) to ascertain the differentially expressed genes (DEGs) 116 between COVID-19 and control sample sets (q-value < 0.01 expression fold-change > 1.5 by DESeq2; 117 Figure 1B , Table S2 ). Separately, SARS-CoV-2 RNA reads were aligned to the SARS-CoV-2 genome 118 and the number of reads was discerned across multiple tissues including the lung, lymph node, kidney, 119 liver, and heart ( Figure S1 ) but mostly in the lung. Viral reads were robustly detected in nasopharyngeal 120 (NP) swab samples from consistent with previous reports. 4, 8 Normalized coverage 121 values in SARS-CoV-2 positive autopsy tissue samples revealed detection bias towards the SARS-CoV-122 2 3' end sequences, which is consistent with the known viral transcript abundance (Figures S1A-B) . 9 123 Reconstruction of the viral genomes revealed known and unknown variants common to many patients, 124 and some evidence of intra-host variability ( Figure S1C) . Coverage limitations notwithstanding, we 125 generally saw evidence of the same viral strain across the organ systems within each patient. We also 126 assessed variability of the COVID-19 patient samples by clustering based on the SARS-CoV-2 viral 127 loads (and noted as SC2 high and SC2 low) and the viral loads were inversely correlated with the 128 duration of disease, independent of factors such as race, age, or gender (Figures S1D-E) . In addition to 129 the annotated clinical metadata table (Table S1) Table S2 ). We observed that each tissue 136 showed its own distinct transcriptional disruption in response to SARS-CoV-2 infection, with the lymph 137 node exhibiting the greatest number of DEGs when compared to controls (in both high and low viral 138 load groups). Of note, both tissue-specific and pan-tissue disruptions of normal expression programs 139 were observed (Figure 1B) , and these were then summarized using gene set enrichment analysis 140 (GSEA, Figures 2A, S2A) . Some pathways were consistently dysregulated in all tissues during early 141 infection (SARS-CoV-2 high), such as G2M checkpoint (q-values of 6.4 × 10 -19 , 3.0 × 10 -5 , 1.2 × 10 -8 , 142 9.7 × 10 -8 , and 0.002 for lung, liver, kidney, lymph node, and heart respectively, Table S2 ), E2F 143 targeting (q-values of 2.8 × 10 -26 , 0.00672, 1.9 × 10 -7 , 9.9 × 10 -9 , 0.047, respectively), and epithelial 144 mesenchymal transition (EMT, q-values of 2.1 × 10 -22 , 3.0 × 10 -4 , 2.9 × 10 -7 , 1.4 × 10 -7 , 0.0287 145 respectively), but in the late infection (SARS-CoV-2 low) gene networks showed more inter-tissue 146 heterogeneity in their disrupted pathways, including cytokine activity and inflammatory response. 147 However, in both the SARS-CoV-2 high and low viral load groups, the G2M checkpoint and E2F 148 networks were consistently upregulated, indicating a core, persistent set of dysregulated cell cycle 149 regulation genes during early and late stages of infection. 150 The DEGs and GSEA results were then examined for the largest differences between infection 151 level and stage (SARS-CoV-2 high, early COVID-19 infection vs. SARS-CoV-2 low, late infection). Interestingly, the heart tissues showed the largest transcriptional differences, revealing that 153 the later stage of the infection had a much greater impact on cardiac tissues ( Figure S2A ). To place 154 these results into a greater context and to compare with the findings to other datasets, we compared 155 DEGs from each tissue to RNA-seq data from NP swabs as well as RNA-seq data from a publicly 156 J o u r n a l P r e -p r o o f 5 available dataset on monocytes from COVID-19 positive and negative patients ( Figure S2B ). 4 While the 157 highest correlations were seen within the same tissue types, most of the tissues with high viral load 158 showed statistically significant, positive correlation with the DEGs in the NP swab samples (q-value < 159 0.01), when compared to normal/negative patients. In contrast, the later infection (low viral load) 160 patients' tissues showed negative correlation with the NP swab samples, indicating that the systemic 161 impact of SARS-CoV-2 can be missed when not considering the biological impact on different organs. 162 Interestingly, when matched with disease severity (high, medium, and low viral load groups within NP 163 swab samples), the difference was bigger in the low and medium groups compared to high groups. 164 To create a more fine-grained analysis of the cellular gene expression states in each tissue, we 165 used the cell deconvolution algorithm MuSiC on each tissue's RNA-seq data (see STAR Methods). The 166 MuSiC results showed distinct disruptions of the transcriptional programs for each tissue in the COVID-167 19 patients and gain or loss of cell types ( Figure 2B) . Consistent with the previous reports, the lung 168 showed a loss of the capillary intermediate cells and alveolar epithelial cell types. 10, 11 Strikingly, we 169 also found decreases in the major cell types in each organ type, suggesting systemic disruption of 170 COVID-19 response. The kidney and liver showed a loss of proximal tubule in the kidney and 171 hepatocyte marker expressions in the liver, but an increase in T cells in both organs. Furthermore, the 172 heart showed a near-complete loss of the cell signatures for cardiomyocytes in both SARS-CoV-2 high 173 and low viral loads (Figures 2B, 3A) , despite no obvious gross or histologic changes in the heart 174 ( Figure 3B ). This observation extends from previously reported cardiovascular involvements in 175 COVID-19 and further defines the SARS-CoV-2 specific transcript and cellular changes in lung as well 176 as other organs such as heart, liver, and kidney. 12, 13 177 We then looked at several markers related to functions and processes of each organ ( Figure 3C) . 178 While the lung showed the biggest changes in response to COVID-19, the loss of functional markers 179 were specific to organ type. For example, surfactant proteins (i.e. SFTPA1, SFTPB, SFTPC), which are 180 components of alveolar lipoprotein complex crucial for gas exchange, were lost in lung but increased in 181 other organs. Similarly, markers associated with liver function (i.e. liver enzymes and proteins such as 182 ALB, HAO1, ALDOB) and solute carrier family proteins (i.e. SLC22A13, SLC34A1), UMOD 183 (uromodulin) were specifically lost in liver and kidney, respectively. In addition to the cardiomyocyte 184 markers ( Figure 3A) , we also found that markers such as PLN (phospholamban, calcium pump 185 inhibitor), HAND1(Heart And Neural Crest Derivatives Expressed 1), and TNNT2 (troponin cardiac 186 type) were specifically lost in heart. This observation suggests that in addition to cell type losses, the 187 discruptions due to COVID-19 affect the biological processes and functions for which each organ 188 system is responsible. Consistent with recent reports related to virus-induced senescence found in 189 COVID-19 lung models 14 , these data also show that each organ system (lung, heart, liver, and kidney) 190 exhibits its own distinct inflammatory response and resultant change of tissue identity. targets for SARS-CoV-2 (i.e., IO360 Panel plus COVID-19 Spike-In, Figure 1A) . patients characterized with total RNA-seq, we identified patients that had high overall SARS-CoV-2 200 expression (SC2 high) or had low overall expression of SARS-CoV-2 (SC2 low) from their lung tissue 201 samples, and four representative samples from each group were selected for further downstream 202 analysis. Serial sections were stained with an RNA scope probe against the viral S gene, Syto13 (nuclear 203 DNA), macrophages (CD68), immune cells (CD45), and epithelial (Pan-cytokeratin) along with the 204 GeoMx Cancer Transcriptome Atlas Panel (CTA, 1811 targets) supplemented with 23 human genes 205 associated with lung biology and two ORFs from the SARS-CoV-2 genome (Figures 1A, S1) . We chose 206 tissue regions (ROIs) that captured three structural components of the lung, including vascular, airway, 207 and alveolar regions (Figures S3). 208 We observed significant differences across tissue types within the lung (DEGs with q-value < 209 0.05 and > 1-fold-change by DESeq2). For example, vascular ROIs showed an increase in ACTA2 and Table S3 ). When we summarized these genes using gene ontology (GO) terms, tissue 217 type specific processes in response to COVID-19 were distinctive from overall inflammation (Table   218 S3). While inflammatory responses are present in all tissue compartments, macrophage and monocyte 219 activation was prominent in alveolar regions while fibrosis occurs near the vascular region. Moreover, 220 type I interferon and cytokine related pathways were found significant in large airway tissues while 221 complement activation was found in vascular tissues. 222 We also compared differences across injury sources (SARS-CoV-2 infection, influenza, and non-223 viral ARDS) and found significant differences between normal and SARS-CoV-2 high samples, even 224 after accounting for compartmental variability (Figures 4B, S4) . These differences included a decrease 225 in expression of surfactant genes (SFTPA1, SFTPB, and SFTPC) associated with type 1 and type 2 226 pneumocytes, as well as an enrichment for genes associated with basal cells (TP63) and club cells We also examined the spatial transcriptome data for differences between the high and low 243 SARS-CoV-2 and the IAV infected lung samples. This analysis revealed a significant enrichment of 244 THBS1 and NR4A1 in the influenza samples, both genes that have been shown to be engaged in 245 response to influenza induced lung injury ( Figure S4B ). When lung tissues from SARS-CoV-2 high and 246 low samples were compared to those from non-viral ARDS, enrichment for S100A8 and S100A9 was 247 observed, which is consistent with the significant enrichment of neutrophils in these samples and 248 previously suggested to be a driver of COVID-19 pathogenesis ( Figure S4A) showed significantly diminished similarity to those of healthy lungs (Figures 5B, S5A-B) . Interestingly, 264 the loss of this similarity did not result in convergence to other tissue types we observed (i.e., loss of 265 alveolar similarity score did not increase the vascular or large airway scores). To evaluate the cause of 266 this lost similarities, we discovered genes attributing disease-and tissue-specific clustering and 267 identified 35 genes with the highest contrast ( Figure 5C ). For example, some of these genes were 268 related to regulatory T cell differentiation in COVID-19 high and low viral load alveolar tissues (PLK1, 269 ATM) and IL6/JAK/STAT3 signaling in SARS-CoV-2 low vascular regions (SOCS1, CXCL11, Table   270 S3). In addition to the known molecular responses to COVID-19, these genes can be used as a set to 271 locate infection response within the lung and disease states. Figure S5C ). We 282 validated these findings by comparing the expression levels with cell-type specific COVID-19 gene 283 signatures derived from single-nucleus RNA-sequencing, 19 which showed enrichments across different 284 cell types ( Figure 5E , Table S3 ). Using an orthogonal approach, we stained the lung tissues with 285 Masson's trichrome and observed a statistically significant increase (p-value < 0.01) in cellular collagen-286 rich areas, confirming the increase in lung fibroblasts ( Figure S3A ). 287 Given the observed changes in cell proportions that are induced during SARS-CoV-2 infection, 288 we next examined the impact on the co-occurrence of these changes as a metric of intrapulmonary In this study, we established a clinical analytical pipeline to collect and examine autopsy samples 325 to elucidate and compare the spatial transcriptional landscape induced by SARS-CoV-2, IAV, and non-326 viral ARDS. By combining transcriptional profiles of 39 patient autopsy tissues from heart, liver, lung, 327 kidney, and lymph nodes, we presented body-wide transcriptome changes in response to Across all tissues, we found system-wide disruptions of cellular and transcriptional pathways and 329 matched the lung data with spatial protein and expression profiling (GeoMx, across 357 tissue sections 330 from 16 representative patient lung samples). We also identified tissue compartment-specific damage 331 (alveolar, vascular, and large airway compartments within the lung tissue) and loss of tissue type 332 identity caused by the SARS-CoV-2 infection, which correlated with viral loads (high vs. low) and the 333 clinical course of infection. When these spatial transcriptomics data were compared to the multi-organ bulk RNA-seq data 366 from the autopsy issues, confirmatory as well as additional signatures of COVID-19 disease were found. 367 First, fibroblasts and immune cells (i.e., macrophages) were increased in most tissue types, while 368 tissues-specific cell types, such as alveolar epithelial types 1 and 2 cells in the lung and cardiomyocytes 369 in the heart, showed a decrease in COVID-19 relative to controls. Increases in fibroblasts, endothelial, Table. 573 574

Patient specimens were processed as described in Butler et al. 4 Clinical metadata is summarized in 576 Table S1 . Briefly, nasopharyngeal (NP) swabs were collected N using the BD Universal Viral Transport Table S2 . healthy ROIs were randomly sampled (1, 5, and 10 ROIs) and compared with the consensus profiles. 658 With these gene profiles, we assessed the similarity of the profile from each ROI with the reference 659 profile by taking cosine similarity (1 being closer to the reference, 0 being orthogonal, Figure S5A ). To 660 identify genes specific to tissue-and disease-states, we performed logistic regression with L1 norm to 661 model the gene expression profiles. The logistic regression was done with glmnet (v4.1-1). 64 The genes 662 with highest coefficients were filtered to identify 35 genes that may distinguish diseased tissue types 663 (Table S3) . for a given target were then collapsed into a single metric by taking the geometric mean of probe counts. 722 A count of 1 was added to any probe that yielded 0 counts before the geometric mean was taken. 

738 Gene outliers were detected by a limit of quantification (LOQ) approach. The LOQ for each AOI was 739 defined as the sample's negative geometric mean multiplied by its negative standard deviation raised to 740 the power of two. Any target (1,837 total) that was not above LOQ in at least 2% of AOIs were deemed 741 prohibitively low expressors and were removed from analysis. This feature-based filtering approach 742 discarded 171 genes (9.3%) leaving 1,666 genes. Genes were normalized by the Q3 approach as above. Each gene has three p-values associated with it (from the pairwise contrasts above). The contrast with 796 the lowest p-value was selected to represent a given gene (i.e., this corresponded well with the corner 797 that the gene was assigned to). P-values were then adjusted to account for multiple comparisons by 798 using the Benjamini-Hochberg procedure. 59 Differentially expressed genes from this analysis is included 799 in Table S3 . The monocyte COVID-19 RNA-Seq data, published under the accession GSE159678, 71 was 834 downloaded from SRA and gene expression was quantified using Salmon's selective alignment 835 approach. 51 The RNA-Seq processing pipeline was implemented using pyrpipe (https://github.com/urmi-836 21/pyrpipe/tree/master/case_studies/Covid_RNA-Seq). 72 Exploratory data analysis and differential 837 expression analysis were performed using MetaOmGraph. 73 SFTPA1  SFTPC  SFTPB  PRX  RTKN2  MYBPC3  TNNI3  TNNT2  HAND1  PLN  AQP2  UMOD  TMEM207  SLC22A13  SLC34A1  ALB  HAO1  ALDOB  APOB  AKR1C4  TBP  ACTB  YWHAZ  HPRT1 SFTPA1  SFTPC  SFTPB  PRX  RTKN2  MYBPC3  TNNI3  TNNT2  HAND1  PLN  AQP2  UMOD  TMEM207  SLC22A13  SLC34A1  ALB  HAO1  ALDOB  APOB  AKR1C4  TBP  ACTB  YWHAZ  HPRT1 1 Park et al. report system-wide transcriptome damage and tissue identity loss wrought by SARS-CoV-2, 2 influenza, and bacterial infection across multiple organs (heart, liver, lung, kidney, and lymph nodes) 3 and provide spatio-temporal landscape of COVID-19 in the lung. 

Temporal dynamics in viral shedding and transmissibility of COVID-19 Nat 852

Clinical Characteristics of Coronavirus Disease

Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the 860 pathogenesis of COVID-19

Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals 873 unique host responses, viral diversification, and drug interactions

Co-infections in people with COVID-19: a 876 systematic review and meta-analysis

Activation and evasion of type I interferon responses by 880 SARS-CoV-2

Evaluation of bacterial co-infections of the respiratory tract in COVID-19 883 patients admitted to ICU

Single-cell reconstruction of the adult human heart during heart failure and recovery reveals the 886 cellular landscape underlying cardiac function

Single-Cell Transcriptomic 898 Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis Am J 899

Lung epithelial 903 and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in 904 fatal COVID-19

Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases JAMA Cardiol 908

Myocardial injury and COVID-19: Possible mechanisms

Virus-induced senescence is a driver and 918 therapeutic target in COVID-19

Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection Nat 925

Elevated Calprotectin and Abnormal Myeloid Cell 932 Subsets Discriminate Severe from Mild COVID-19

A distinct innate immune signature marks progression from mild to severe 937 COVID-19

Single-cell landscape of bronchoalveolar immune cells in patients 941 with COVID-19

& Izar B (2021) A molecular single-cell 948 lung atlas of lethal COVID-19

T cell-mediated immune response to respiratory 951 coronaviruses

HLA-C as a mediator of natural killer and T-cell 953 activation: spectator or key player?

Differential expression of human major histocompatibility class I loci

exome sequencing identifies susceptibility genes and pathways for idiopathic pulmonary fibrosis 960 in the

Genome-wide association 965 meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis

Quantitative proteomic characterization of lung tissue in idiopathic pulmonary fibrosis

Mechanical forces induce an asthma gene signature in healthy airway epithelial cells Sci

Profiling of 977 immune dysfunction in COVID-19 patients allows early prediction of disease progression

Spatial mapping of SARS-CoV-2 and H1N1 lung injury 981 identifies differential transcriptional signatures

COVID-19 tissue atlases reveal SARS-CoV-2 pathology 997 and cellular targets

& Team YIR (2020) Sex 1010 differences in immune responses that underlie COVID-19 disease outcomes

Longitudinal analyses reveal immunological 1025 misfiring in severe COVID-19

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and 1031 Associations with

The spatial landscape of lung pathology during COVID-19 progression 1036

Pathological features of COVID-19-associated myocardial 1039 injury: a multicentre cardiovascular pathology study

& Iyengar R (2020) 1045 Physiology of cardiomyocyte injury in COVID-19 medRxiv Prepr Serv Heal Sci

Targets of 1049

Severe Acute Respiratory Syndrome Coronavirus 2: The Clue for Coronavirus Disease

Patrolling monocytes promote the pathogenesis of early lupus-like 1053

Pathological inflammation in patients with COVID-19: a key role 1055 for monocytes and macrophages

immunopathogenesis and Immunotherapeutics Signal Transduct Target Ther

TenOever BR A Molecular Basis of Long COVID-19

CC (2021) A diagnostic host response biosignature for COVID-19 from RNA profiling of nasal 1067 swabs and blood

Early introductions and transmission of SARS-CoV-2 1075 variant B.1.1.7 in the United States

Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and 1080

Hidden genomic diversity of SARS-CoV-2: 1084 implications for qRT-PCR diagnostics and transmission bioRxiv Prepr Serv Biol

Multiplex digital spatial 1089 profiling of proteins and RNA in fixed tissue

Advances 1092 in mixed cell deconvolution enable quantification of cell types in spatially-resolved gene 1093 expression data bioRxiv

The nf-core framework for community-curated bioinformatics pipelines Nat 1098

FastQC: A Quality Control Tool for High Throughput Sequence Data

STAR: ultrafast universal RNA-seq aligner

Salmon provides fast and bias-1105 aware quantification of transcript expression

Transcriptome 1108 assembly from long-read RNA-seq alignments with

Moderated estimation of fold change and dispersion for 1111

RNA-seq data with

Bulk tissue cell type deconvolution with 1114 multi-subject single-cell expression reference

A molecular cell atlas of the human lung from single-cell RNA sequencing 1119

Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations 1125

Spatiotemporal immune zonation of the human 1131 kidney Science

Next-generation computational tools for 1133 interrogating cancer immunity

Controlling the False Discovery Rate: A Practical and 1136

Molecular signatures database (MSigDB) 3.0 Bioinformatics

Gene set enrichment analysis: A 1143 knowledge-based approach for interpreting genome-wide expression profiles

Enrichr: a comprehensive gene set enrichment analysis web server 2016 update Nucleic 1148

cocor: A Comprehensive Solution for the Statistical 1150 Comparison of

Regularization Paths for Generalized Linear Models 1152 via Coordinate Descent

Single-Cell Transcriptomics of Human and Mouse 1156

Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species Immunity 1157

lmerTest Package: Tests in Linear 1159 Mixed Effects Models

Statistical methods for identifying differentially expressed 1162 genes in RNA-Seq experiments

The reactome 1166 pathway knowledgebase

GSVA: gene set variation analysis for microarray 1169 and RNA-Seq data

Quantification of histochemical staining by color deconvolution 1171

Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons Cell Reports 1176

pyrpipe: a Python package for RNA-Seq 1178

MetaOmGraph: a workbench for interactive 1180 exploratory data analysis of large expression datasets

Improved metagenomic analysis with Kraken 2 Genome 1183

Fast and accurate short read alignment with Burrows-Wheeler transform 1185

Loman 1188 NJ, & Andersen KG (2019) An amplicon-based sequencing framework for accurately measuring 1189 intrahost virus diversity using PrimalSeq and iVar

LymphNode Lung Liver Kidney Heart * *** * * * ** ** *** * ***